We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q3 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that McKesson (MCK - Free Report) will announce quarterly earnings of $9.31 per share in its forthcoming report, representing an increase of 15.9% year over year. Revenues are projected to reach $105.54 billion, increasing 10.8% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenue- Medical-Surgical Solutions' of $3.05 billion. The estimate suggests a change of +3.3% year over year.
The consensus estimate for 'Revenue- Prescription Technology Solutions' stands at $1.50 billion. The estimate indicates a change of +9.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- North American Pharmaceutical' will likely reach $88.31 billion. The estimate indicates a year-over-year change of +1.4%.
Analysts forecast 'Adjusted Operating Profit- Medical-Surgical Solutions' to reach $278.29 million. The estimate is in contrast to the year-ago figure of $294.00 million.
It is projected by analysts that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $264.40 million. Compared to the present estimate, the company reported $235.00 million in the same quarter last year.
Analysts predict that the 'Adjusted OPERATING PROFIT- North American Pharmaceutical' will reach $855.65 million. The estimate compares to the year-ago value of $944.00 million.
Over the past month, shares of McKesson have returned +0.3% versus the Zacks S&P 500 composite's +0.9% change. Currently, MCK carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q3 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics
Analysts on Wall Street project that McKesson (MCK - Free Report) will announce quarterly earnings of $9.31 per share in its forthcoming report, representing an increase of 15.9% year over year. Revenues are projected to reach $105.54 billion, increasing 10.8% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenue- Medical-Surgical Solutions' of $3.05 billion. The estimate suggests a change of +3.3% year over year.
The consensus estimate for 'Revenue- Prescription Technology Solutions' stands at $1.50 billion. The estimate indicates a change of +9.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- North American Pharmaceutical' will likely reach $88.31 billion. The estimate indicates a year-over-year change of +1.4%.
Analysts forecast 'Adjusted Operating Profit- Medical-Surgical Solutions' to reach $278.29 million. The estimate is in contrast to the year-ago figure of $294.00 million.
It is projected by analysts that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $264.40 million. Compared to the present estimate, the company reported $235.00 million in the same quarter last year.
Analysts predict that the 'Adjusted OPERATING PROFIT- North American Pharmaceutical' will reach $855.65 million. The estimate compares to the year-ago value of $944.00 million.
View all Key Company Metrics for McKesson here>>>Over the past month, shares of McKesson have returned +0.3% versus the Zacks S&P 500 composite's +0.9% change. Currently, MCK carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .